Zealand Pharma Reports P-III (EASE 1) Trial Results of Glepaglutide for the Treatment of Short Bowel Syndrome
Shots:
- The P-III (EASE 1) trial evaluating glepaglutide (10mg, qw, BIW, SC) vs PBO in ~108 patients with SBS associated with intestinal failure who were dependent on PS for 3 days/wk.
- The trial met its 1EPs i.e., patients treated with glepaglutide (BIW) achieved a reduction in weekly parenteral support volume by 5.13L/wk. from baseline @24wks.; 3.13L/wk. for patients with glepaglutide (qw); 2.85L/wk. in PBO, 66% of patients in BIW had a clinical response (>20% reduction in parenteral support volume); 45.7% & 38.9% in qw & PBO treatment groups
- The therapy was safe & well-tolerated, 14% were completely weaned off parenteral support in the BIW dosing group, 9 achieved enteral autonomy while no PBO-treated patients were able to discontinue parenteral support
Ref: Globenewswire| Image: Zealand Pharma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
